About this trial
In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. PCOS is one of the most common endocrine disorders affecting about 4% to 8% of women of reproductive age. Diagnosis is primarily clinical with Rotterdam criteria being the most commonly followed criteria, which require the presence of two out of the three criteria including oligo and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound.
The objective of this study is to compare the outcome of Metformin versus Myo-inositol in the management of polycystic ovarian disease.
Eligibility criteria
Qualifiers
Married or unmarried
Diagnosed with PCOS (females presenting with compliant of irregular cycle for >3 months, with hirsutism, acne, presence of polycystic ovaries detected on ultrasound ).
Disqualifiers
Females already taken or taking PCOS treatment (on medical record)
Females already enrolled in another trial program
Females already taking trial drugs
Females with chronic diabetes (BSR>200 mg/dl), hypertension (BP≥140/90mmHg)
Trial design
Treatments tested in this trial
- Myoinositol
- Metformin
Treatment groups
Sponsors and collaborators
Fatima Tariq
Lead sponsor
Combined Military Hospital Gujranwala
Sponsor institution